Date published: 2025-12-24

1-800-457-3801

SCBT Portrait Logo
Seach Input

CD300LF Inhibitors

CD300LF inhibitors, in the context of this list, refer to chemicals that may not directly target CD300LF but influence its activity through modulation of immune response pathways. The inhibitors primarily focus on immunosuppressive and anti-inflammatory mechanisms, as CD300LF plays a significant role in immune system regulation. These inhibitors encompass a broad range of mechanisms, including calcineurin inhibition (Cyclosporin A, Tacrolimus), mTOR inhibition (Rapamycin, Sirolimus), modulation of cytokine signaling (Tofacitinib), and interference with nucleotide synthesis essential for lymphocyte proliferation (Mycophenolate Mofetil, Methotrexate, Leflunomide). The use of these inhibitors provides insight into the complex network of immune response regulation, highlighting how modulation of one pathway can influence the activity of related proteins such as CD300LF. For example, by reducing cytokine production or lymphocyte proliferation, these chemicals can indirectly impact the activation and function of cells expressing CD300LF, such as natural killer cells and certain types of T-cells. This approach to inhibition is particularly relevant in the context of autoimmune diseases or conditions where the immune response needs to be controlled or suppressed. Moreover, the diversity of these inhibitors' chemical structures and their targeted pathways underscores the intricate nature of immune system regulation. From corticosteroids like Dexamethasone, which broadly suppress immune function, to more targeted approaches like JAK inhibition by Tofacitinib, these compounds offer various strategies to modulate the immune system. The indirect effects on CD300LF-related pathways demonstrate the interconnectedness of immune signaling and the potential for chemical compounds to influence these networks in a multifaceted manner. As research advances, a deeper understanding of these interactions may lead to more direct and specific inhibitors of CD300LF, providing targeted approaches for modulating immune responses in various pathological conditions.
Product NameCAS #Catalog #QUANTITYPriceCitationsRATING

Cyclosporin A

59865-13-3sc-3503
sc-3503-CW
sc-3503A
sc-3503B
sc-3503C
sc-3503D
100 mg
100 mg
500 mg
10 g
25 g
100 g
$62.00
$90.00
$299.00
$475.00
$1015.00
$2099.00
69
(5)

Cyclosporin A is an immunosuppressant that inhibits calcineurin, thereby reducing IL-2 production and influencing T-cell activation, which may indirectly affect CD300LF-related pathways.

Rapamycin

53123-88-9sc-3504
sc-3504A
sc-3504B
1 mg
5 mg
25 mg
$62.00
$155.00
$320.00
233
(4)

Rapamycin is an mTOR inhibitor, which plays a crucial role in T-cell proliferation and activation, potentially impacting pathways associated with CD300LF.

Dexamethasone

50-02-2sc-29059
sc-29059B
sc-29059A
100 mg
1 g
5 g
$76.00
$82.00
$367.00
36
(1)

Dexamethasone is a corticosteroid with potent anti-inflammatory properties, influencing immune responses that could indirectly modulate CD300LF activities.

Mycophenolate mofetil

128794-94-5sc-200971
sc-200971A
20 mg
100 mg
$36.00
$107.00
1
(1)

This agent inhibits inosine monophosphate dehydrogenase, crucial for purine synthesis in lymphocytes, indirectly affecting pathways related to CD300LF.

FK-506

104987-11-3sc-24649
sc-24649A
5 mg
10 mg
$76.00
$148.00
9
(1)

FK-506 binds to FKBP-12, inhibiting calcineurin and thus T-cell activation, potentially impacting CD300LF-associated immune responses.

Azathioprine

446-86-6sc-210853D
sc-210853
sc-210853A
sc-210853B
sc-210853C
500 mg
1 g
2 g
5 g
10 g
$199.00
$173.00
$342.00
$495.00
$690.00
1
(1)

Azathioprine is an immunosuppressive antimetabolite, which can influence immune responses linked to CD300LF.

Methotrexate

59-05-2sc-3507
sc-3507A
100 mg
500 mg
$92.00
$209.00
33
(5)

Methotrexate is a dihydrofolate reductase inhibitor, affecting lymphocyte proliferation, which may influence CD300LF-related pathways.

Leflunomide

75706-12-6sc-202209
sc-202209A
10 mg
50 mg
$20.00
$81.00
5
(1)

Leflunomide inhibits dihydroorotate dehydrogenase, affecting pyrimidine synthesis and thus impacting T and B cell function, potentially influencing CD300LF pathways.

hydroxychloroquine

118-42-3sc-507426
5 g
$56.00
1
(0)

Hydroxychloroquine, primarily used for malaria and autoimmune diseases, can modulate immune activity, potentially impacting CD300LF pathways.